Serina Therapeutics Q2 net loss widens on higher expenses

Serina Therapeutics

13/08/2026 21:25

Overview
US biotech firm reported no Q2 revenue and a wider net loss yr/yr
Q2 operating expenses rose due to higher R&D and legal costs

Result Drivers
R&D SPENDING - Co said higher Q2 R&D expenses were driven by increased headcount and greater clinical-related activity
LEGAL AND FINANCING COSTS - Co attributed higher Q2 general and administrative expenses to legal expenses associated with patent and financing activities

Company press release: ID:nGNX6fPLvd

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Income From Operations
 
-$6.78 mln
 
Q2 Operating Expenses
 
$6.78 mln
 

Analyst Coverage
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy."
Wall Street's median 12-month price target for Serina Therapeutics, Inc. is $9.50, about 236.9% above its August 12 closing price of $2.82

Reuters Recommended Reads
Aug 13 - Kodiak Sciences Q2 net loss widens on higher R&D costs
Aug 12 - Longeveron Q2 net loss widens on higher legal, clinical trial costs
Aug 12 - Eloxx Pharmaceuticals Q2 net loss widens on higher expenses

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)